Status:
RECRUITING
ExosoMe as Integrative Tool for pRognostic Stratification of Adverse Cardiac remodeLing in stEmi Patients: the MIRACLE Study
Lead Sponsor:
Centro Cardiologico Monzino
Collaborating Sponsors:
Istituto Auxologico Italiano
Conditions:
STEMI
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter observational prospective study aimed to assess whether plasma exosomes can help identify, at an early stage, patients at high risk of adverse remodeling after STEMI (ST-elevatio...
Detailed Description
Adverse cardiac remodeling is a process of structural and functional changes associated with worse clinical outcomes and increased mortality, which occurs in response to sustained pathophysiological s...
Eligibility Criteria
Inclusion
- chest pain suggestive of myocardial ischemia lasting \>30 min
- electrocardiogram (ECG) showing ST-segment elevation \>0.1 mV in more or equal to 2 limb leads or \>0.2 mV in more or equal to 2 contiguous precordial leads, or presumed new left bundle-branch block
- successful treatment with pPCI within 12 h from the onset of symptoms
Exclusion
- previous myocardial infarction (MI)
- time to pPCI \>12 h
- atrial fibrillation
- renal failure with glomerular filtration \<30 ml/min
- claustrophobia
- other contraindications to CMR.
Key Trial Info
Start Date :
May 3 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06070974
Start Date
May 3 2023
End Date
April 30 2026
Last Update
October 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Centro Cardiologico Monzino
Milan, Milan, Italy, 20138
2
Istituto Auxologico Italiano
Milan, Italy, 20149